Author name: ACS Admin

Scripps proprietary glycoprotein technology key to development of new diagnostic tests enabling the design of better, more effective vaccine programs for Lassa fever Zalgen Labs LLC (Zalgen), a biotechnology and diagnostics company focused on high-impact, neglected infectious diseases including Lassa Fever (LF), today announced that it has licensed proprietary technology developed by structural biologist Erica […]

Article in Nature Medicine reports data from study at the University of Texas Medical Branch at Galveston (UTMB) showing protection against Lassa Fever, a major threat to global health Zalgen Labs LLC (Zalgen), a biotechnology and diagnostics company focused on high-impact, neglected infectious diseases including Lassa Fever (LF), today announced that Arevirumab-3, its lead immunotherapeutic

Article in Science provides template for advanced vaccine and immunotherapeutic design against Lassa Fever, a major threat to global health Zalgen Labs LLC (Zalgen), a biotechnology and diagnostics company focused on high-impact, neglected infectious diseases including Lassa Fever (LF), today announced that its human monoclonal antibodies were used in an extensive research collaboration of the

Zalgen Labs, a biotechnology and diagnostics company focused on high-impact, neglected infectious diseases, announced that it has received via transfer the viral hemorrhagic fever diagnostics business from Corgenix Medical Corporation and opened an advanced product development center in the Fitzsimons Bioscience Park Center on the University of Colorado Anschutz Medical Campus in Aurora, Colo. Zalgen